Biocrates
Private Company
Total funding raised: $7M
Overview
Biocrates is a pioneer and established leader in the field of quantitative metabolomics, offering a suite of standardized, kit-based solutions and services for mass spectrometry analysis. With over 20 years of experience, the company has built a strong reputation for reproducibility and has fostered a global community of over 100 core facilities, CROs, and research institutions. Its technology is validated by thousands of publications and is critical for research in disease mechanisms, nutrition, microbiome interactions, and biomarker discovery. The company operates as a private, revenue-generating diagnostics and services provider, helping to scale metabolomics for partners worldwide.
Technology Platform
Standardized, kit-based mass spectrometry platform for quantitative metabolomics, integrating wet-lab assays, standardized protocols, and software (WebIDQ, QMDB) for end-to-end workflow from sample to data.
Funding History
2Opportunities
Risk Factors
Competitive Landscape
Biocrates competes with other targeted metabolomics service providers, core facilities offering in-house methods, and broad-based life science tools companies (e.g., Thermo Fisher, Agilent, Waters) that sell MS instruments and associated consumables. Its key differentiation is its dedicated focus on standardized, kit-based quantification, which offers superior reproducibility compared to most custom or service-based approaches.